New injections aim to melt liver fat in MASH patients
NCT ID NCT07660848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 weeks. The main goal is to see if these injections can safely reduce liver fat content, measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4729 injection and HRS9531 injection
What this could lead to
If successful, these injections could offer a new way to reduce liver fat and control MASH, potentially preventing progression to cirrhosis.
What could go wrong
This is an early Phase 2 trial with only 160 participants. The drugs may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, 102218, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact